Just for interest ....
Spark Plus posted this ANP announcement on LinkedIn recently and the post was liked by a Study Manager from Roche Diagnostics.
It's interesting because Roche is such a large player in COVID diagnostics as well as DMD potentially (via Sarepta).
It would be nice if Roche is taking a close look at ANP's research .... could be just a coincidence though.
DYOR, not advice etc
News: ANP Antisense Therapeutics Submits Clinical Trial Application For Atl1102 Phase Iib Dmd Trial..., page-18
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $54.97K | 528.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 396468 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 99708 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |